Philip J. Johnson
University of Liverpool(GB)Morpho (United States)(US)Virginia Commonwealth University(US)Missouri College(US)Health Innovations (United States)(US)Auburn University(US)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Hepatitis C virus research, Viral-associated cancers and disorders
Most-Cited Works
- → Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade(2014)2,678 cited
- → Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study(2015)1,232 cited
- → Meeting report: International autoimmune hepatitis group(1993)1,100 cited
- → Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study(2013)766 cited
- → Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial(2019)694 cited
- → Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors